• Medicine 1

    When patients are involved, medical research results become meaningful solutions

  • Medicine 2

    We provide patient input to the latest research for chronic diseases

  • Medicine 3

    Improving patient knowledge and involvement in clinical trials

MedecinesClinicalTrialsIn the 1800’s, early drugs were derived from plant and supplemented by animal materials and minerals. These drugs were mainly discovered through a combination of trial and error experimentation, observation of human and animal reactions and they were the only available treatments until recent times. Scientific techniques to drug discovery and development began in the 1800’s.

From then onwards, more and more drugs were discovered, tested and synthesized in large-scale manufacturing plants. But drugs are not ordinary consumer products. In most instances, consumers are not in a position to decide when to use drugs, which drugs to use, how to use them and to weighing potential benefits against risks. No medicine is completely safe. Professional advice from prescribers or dispensers is necessary in making these decisions.

Pharmacovigilance in the European Union

All medicinal products for human use commercial in the European Union are authorised either by the EU or a Member State before they enter the European single market. To be authorised, they need to comply with the good manufacturing practice guidelines applicable within the European Economic Area. Medicinal products are then monitored through their lifespan to guarantee that in the case of adverse reaction or unacceptable risk they can be quickly withdrawn from the market. This is done through the EU system of pharmacovigilance.

Through the European Medicines Agency (EMA) established in 1994, the EU coordinates the scientific evaluation of the quality, safety and efficacy of medicinal products and provides scientific advice to ensure the highest possible level of public health protection. Since 2010, EFA has been a member of the Patients’ and Consumers’ Working Party (PCWP) of the European Medicines Agency (EMA). We are closely involved in EMA activities to bring the patient perspective for asthma, allergy and COPD medicines.

As end-users of medicines, we at EFA advocate for:

  • An improved involvement of patients in all decisions influencing their health, especially when it comes to risk-benefit analysis and safety;
  • Stricter controls that guarantee the safety of the medicines entering the EU single market.

Our advocacy activities on medicines and clinical trials are voiced and supported by the European Patients’ Forum (EPF), an EU umbrella organisation of which we are full members.

EFA documents and activities in medicines

What's new - Medicines

EFA will participate this September in two leading respiratory and dermatology conferences, where we will expose our projects and bring our patients perspective to those fields.  From the 9 to 13 ...

Read more...

EFA’s Susanna Palkonen represented the patient view for us and the European Patients' Forum in a panel discussion “The access to medicines – Challenges and perspectives for Europe” hosted by the Bavar ...

Read more...

Latest research - Medicines

During the summer, EFA had the chance to provide feedback on the development of the work programme 2018-2020 of Horizon 2020 (the European Union’s Research and Innovation Framework Programme) in respo ...

Read more...

The University of Leicester has led a ground-breaking study, funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and EU-funded project AirPROM, on a new drug that may in  ...

Read more...

Key Facts

34 national bodies

authorising medicines in Europe are recognised by EMA